While response of HNSCC patients to EGFR targeted therapy is not correlated to expression or amplification of EGFR [3, 14], we found that HNSCC cell lines with high expression of ANO1 showed enhanced sensitivity to Gefitinib. This evidence concerns the gene ANO1 and head and neck squamous cell carcinoma.